OakChart

Cerenome Inc

CNSYHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 3:59 PM ET

0.77-0.03 (-3.75%)
2026-11-13 04:46 CET
Market cap
$5.85M
Revenue, TTM
4.20 USD m
Net income, TTM
-26.09 USD m
Free cash flow, TTM
-23.55 USD m
EPS diluted, TTM
-4.41
Price / earnings
-
Compare

Price

CNSY against its 20, 50 and 200-day averages
Terms2050200Miss
Patternshover a marker to name it
Sales mean, own scale
RS 0Sales 0.92Price0.751.320.002.505.007.5010.0014.5M29.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CNSYclose 0.7720-day 1.3350-day 1.74200-day 4.360.77

95.9% under the 52-week high of 18.89 on 12 Dec 2025. 52-week low 0.43 on 10 Nov 2026. Last 15 sessions, 890.7% high to low

Volume 0.50× normal · the line is the 50-bar volume average

Setup. RS line 0
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 1 of 5 — fails: RSI (14): Not Oversold (>50); 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 0 of 4 — fails: Institutional Ownership: Over 30%; Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

CNSY
52-week range, 2% of the way up
0.4318.89

Cerenome, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Employees28
IPOOct 22, 2003
Beta1.49
ATR, 14d0.31
Rel volume0.50
Short float11.27%
Insider own1.30%
Inst own16.30%

Snapshot

6 groups

Valuation

Index-
Market Cap$5.85M
Enterprise Value-2.70M
Income-26.09M
Sales4.20M
Book / share0.75
Cash / share1.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees28
IPOOct 22, 2003

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales1.39
Price / book1.03
Price / cash0.68
Price / free cash flow-
Value / cash profit-
Value / sales-0.64
Quick Ratio1.35
Current Ratio1.35
Debt / equity0.01
Long-term debt / equity0.00
Options and shortNo / Yes

Earnings

Earnings / share-4.41
Earnings next year-2.48
Earnings next quarter-0.95
Earnings this year38.90%
Earnings next year43.94%
Earnings growth, 5 years64.48%
Past earnings growth70.82% 59.95%
Past sales growth185.50% 76.66%
Earnings vs last year91.97%
Sales vs last year-20.95%
Earnings vs last quarter-701.84%
Sales vs last quarter-70.43%
EarningsAug 14 AMC
Surprise-48.86% -63.08%

Ownership

Insiders own1.30%
Insider trades0.00%
Institutions own16.30%
Institution trades3.91%
Return on assets-214.01%
Return on equity-614.05%
Return on capital-477.54%
Gross Margin89.58%
Operating margin-628.12%
Profit Margin-620.70%
20-day average-42.05%
50-day average-55.78%
200-day average-82.34%

Technical

Shares out7.59M
Shares floating7.49M
Short / float11.27%
Short ratio1.32
Short interest0.84M
52-week high18.89 -95.9%
52-week low0.43 +79.7%
Volatility28.44% 30.42%
Average range0.31
Strength index29.56
Market sensitivity1.49
Relative volume0.50
Avg Volume640.91K
Volume318,741

Performance

Perf Week15.02%
Perf Month-54.41%
Perf Quarter-79.06%
Perf Half Y-86.62%
Perf YTD-93.98%
Perf Year-94.47%
Perf 3Y-97.79%
Perf 5Y-99.88%
Perf 10Y-100.00%
Recommendation1.00
Target Price28.67
Prev Close0.80
Price0.77
Change %-3.81%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Feb 03, 2026InitiatedLake StreetBuy$2+159.6%
Sep 03, 2025UpgradeD. Boral CapitalHold → Buy$5+548.9%
Mar 17, 2025InitiatedD. Boral CapitalBuy$9+1,068.1%
Jan 25, 2021InitiatedLadenburg ThalmannBuy$8+938.3%
Oct 16, 2020InitiatedMaxim GroupBuy$6+678.7%

Peers

Mkt cap
TickerCompanyMkt cap
CNSPCns Pharmaceuticals Inc5.29M
LTRNLantern Pharma Inc6.88M
NTHINeOnc Technologies Holdings Inc139.92M
CLRBCellectar Biosciences Inc11.65M
KZIAKazia Therapeutics Limited ADR79.44M
RADXRadiopharm Theranostics Ltd ADR12.40M
TLXTelix Pharmaceuticals Ltd ADR3.19B
ACTUActuate Therapeutics Inc16.28M
MBRXMoleculin Biotech Inc8.47M
CATXPerspective Therapeutics Inc101.73M

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
van Es-Johansson AnDirectorOct 01 '26Option Exercise0.0092101,843Oct 01 08:00 AM
Hawkins Richard JDirectorOct 01 '26Option Exercise0.0092102,450Oct 01 08:00 AM
Sims Andrew John Hugh MacIntyrChief Financial OfficerOct 01 '26Option Exercise0.002,985012,926Oct 01 08:00 AM
Clowes HowardDirectorOct 01 '26Option Exercise0.0092102,902Oct 01 08:00 AM
HEDRICK MARC HChief Executive OfficerOct 01 '26Option Exercise0.0016,439060,922Oct 01 08:00 AM
ANDREWS RONALD ASBURYDirectorOct 01 '26Option Exercise0.0092101,843Oct 01 08:00 AM
Guse KyleDirectorOct 01 '26Option Exercise0.0092101,843Oct 01 08:00 AM
Guse KyleDirectorJul 01 '26Option Exercise0.009220922Jul 01 04:30 PM
ANDREWS RONALD ASBURYDirectorJul 01 '26Option Exercise0.009220922Jul 01 04:30 PM
van Es-Johansson AnDirectorJul 01 '26Option Exercise0.009220922Jul 01 04:30 PM
HEDRICK MARC HChief Executive OfficerJul 01 '26Option Exercise0.0016,439044,483Jul 01 04:30 PM
Clowes HowardDirectorJul 01 '26Option Exercise0.0092201,981Jul 01 04:30 PM
Hawkins Richard JDirectorJul 01 '26Option Exercise0.0092201,529Jul 01 04:30 PM
Sims Andrew John Hugh MacIntyrChief Financial OfficerJul 01 '26Option Exercise0.002,98509,941Jul 01 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
VXFVanguard Extended Market Index ETFAUM: 30.79B
IWCiShares Micro-Cap ETFAUM: 1.23B

News

latest 14 of 100
  • Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16 (GlobeNewswire)
  • Cerenome Appoints Director Ron Andrews as Chief Business Officer (GlobeNewswire) +19.01%
  • Cerenome Secures National In-Network Agreement with Aetna for CNSide (GlobeNewswire) -31.42%
  • Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ in Recurrent Glioblastoma (GlobeNewswire)
  • Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ Doses in Leptomeningeal Metastases (GlobeNewswire) +5.73%
  • Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ (GlobeNewswire)
  • What Is The Case For Waiting On Moderna Stock? (Trefis) -9.57%
  • Where Could Moderna's Next Growth Come From? (Trefis) -6.22%
  • Cerenome Secures In-Network Agreement with Florida Blue for CNSide CSF Tumor Cell Enumeration and Molecular Profile Tests (GlobeNewswire) +9.48%
  • Cerenome Launches CNSide CSF Molecular Profile Tests (GlobeNewswire)
  • Cerenome Expects $1.55 Million in CNSide Third Quarter Gross Billings (GlobeNewswire)
  • Cerenome to Hold CNSide Business Update Call on September 30, 2026 (GlobeNewswire) +6.42%
  • Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide Contracted Coverage to Approximately 158 Million Covered Lives (GlobeNewswire) +6.84%
  • Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-1.310-0.880-1.3100.411.113
2026Q12026-05-15-1.050-0.848-1.0451.030.975
2025Q42026-03-12-0.834-0.800-1.0301.361.235
2025Q32025-10-30-1.000-0.500-1.0291.401.494
2025Q22025-08-140.500-2.250-0.1631.391.493
2025Q12025-05-30-29.750-6.203-29.8641.061.484
2024Q42025-03-27-9.500-12.418-16.5491.401.503
2024Q32024-11-14-9.250-14.063-9.1461.461.474
2024Q22024-08-14-11.250-13.250-6.8421.281.703
2024Q12024-05-15-18.750-27.250-18.8641.681.702
2023Q42024-03-05-13.750-26.813-21.0611.271.424
2023Q32023-10-31-25.000-21.918-24.9511.241.863
2023Q22023-08-14-14.750-43.168-14.7651.901.053
2023Q12023-04-20-52.500-51.563-51.7760.510.734
2022Q42023-02-23-56.250-56.250-63.1460.151.484
2022Q32022-10-20-71.250-75.938-71.3210.420.304

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3,101--1,3377.006.50
2020FY-697.5-557.5-697.940.300.30
2021FY-416.25-401.25-415.630.000.00
2022FY-288.75-276.56-289.590.221.35
2023FY-106-115.81-105.994.914.66
2024FY-48.750-46.625-58.5175.825.53
2025FY-7.250-6.050-7.2505.215.20
2026FY--4.430--3.88
2027FY--2.483--20.17
2028FY--0.325--45.58
2029FY-1.630--121.32
2030FY-2.920--173.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-293020.920.501.26
2026Q3S2026-09-302020.750.501.00
2026Q3S2026-09-092011.250.502.00
2026Q3S2026-08-282001.501.002.00
2026Q3S2026-08-173001.421.002.00
2026Q3S2026-08-163001.421.002.00
2026Q3S2026-08-013001.421.002.00
2026Q3S2026-06-213011.421.002.00
2026Q3S2026-05-274011.471.002.00
2026Q3S2026-05-214031.471.002.00
2026Q3S2026-05-195031.320.752.00
2026Q3S2026-05-185031.320.752.00
2026Q3S2026-04-085031.520.753.00
2026Q3S2026-04-064031.650.753.00

Estimate history

EPS, annual-1543481.251-32616.375-1336.605-697.943-415.631-289.586-105.988-58.517-7.193-4.4099
Period201720182019202020212022202320242025TTM
EPS, quarterly-6.842-9.146-16.549-29.864-0.163-1.029-1.03-1.045-1.305
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual2.6892.9836.9980.30300.2244.9135.8245.2134.2
Period201720182019202020212022202320242025TTM
Sales, quarterly1.2791.4561.4121.0591.391.3971.3671.0280.411
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00.0010.010.0180.0410.090.1810.2365.5477.31
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.2280.2360.2360.683.6875.2645.5475.5577.31
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue4.205.215.824.910.220.000.307.002.98
Cost of Goods Sold Incl. D&A0.440.450.850.740.710.42--2.37
Gross Profit3.774.774.974.17-0.49-0.42--1.30
Selling, General and Administrative Excl. Other30.1620.0719.6717.4919.2211.768.7410.2110.77
Research and Development12.518.3810.589.699.705.322.705.375.52
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-26.40-15.30-14.70-13.32-19.71-12.18-8.80-3.66-8.16
Interest Expense-3.613.720.400.710.931.111.851.92
Unusual Expense0.002.63-5.650.00-0.000.24-1.62-2.17-1.16
Net Income Before Taxes-26.09-22.39-12.98-13.32-20.27-13.40-8.24-3.28-8.88
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-26.09-22.39-12.98-13.32-20.27-13.40-8.24-3.28-8.88
Net Income From Continuing Operations-26.09-22.39-12.98-13.32-20.27-13.40-8.24-3.28-8.88
Net Income-26.09-22.39-12.98-13.32-20.27-13.40-8.24-4.93-15.12
EPS (Recurring)-3.78-6.60-71.37-105.99-289.59-410.33-793.92-1,748.94-34,372.32
EPS (Basic, Before Extraordinaries)-4.41-7.19-48.86-105.99-289.59-415.63-697.94-1,336.61-32,616.38
EPS (Diluted)-4.41-7.19-58.52-105.99-289.59-415.63-697.94-1,336.61-32,616.38
EBITDA-25.96-14.85-13.84-12.58-19.00-11.76-8.43-3.22-7.78
Non-Operating Income (Expense)0.33-0.85-0.210.400.15-0.050.050.060.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.091.540.550.570.610.610.250.130.35
Price To Sales Ratio7.177.651.521.1237.16-29.520.470.85
Gross Margin89.5891.4685.3784.84-217.86---43.51
Operating Margin-628.12-293.46-252.32-271.14-8,800.00--2,905.28-52.26-273.62
Net Margin-620.70-429.43-222.84-271.04-9,051.34--2,719.80-70.49-506.91
Shares Outstanding7.315.550.240.180.090.040.020.010.00
Market Capitalization5.855.856.787.9210.3216.2913.639.314.30

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.411.031.371.401.391.061.411.46
Cost of Goods Sold Incl. D&A0.150.110.090.090.090.180.230.23
Gross Profit0.260.921.271.311.300.881.181.22
Selling, General and Administrative Excl. Other9.328.047.025.792.844.415.085.02
Research and Development4.262.872.942.441.251.762.192.86
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.06-7.12-5.74-4.48-1.54-3.54-3.90-3.80
Interest Expense0.010.02---3.760.060.06
Unusual Expense0.000.000.000.00-6.519.140.00-0.96
Net Income Before Taxes-9.01-6.95-5.71-4.425.15-17.40-3.90-2.87
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-9.01-6.95-5.71-4.421.19-17.40-3.90-2.87
Net Income From Continuing Operations-9.01-6.95-5.71-4.421.19-17.40-3.90-2.87
Net Income-9.01-6.95-5.71-4.421.19-17.40-3.90-2.87
EPS (Recurring)-1.31-1.05-1.03-1.03-0.71-18.88-16.55-11.28
EPS (Basic, Before Extraordinaries)-1.31-1.05-1.03-1.030.62-29.86-16.55-9.15
EPS (Diluted)-1.31-1.05-1.03-1.03-0.16-29.86-16.55-9.15
EBITDA-8.91-7.01-5.65-4.40-1.45-3.35-3.67-3.57
Non-Operating Income (Expense)0.060.190.030.060.18-0.960.050.03
Other After Tax Adjustments0.000.000.000.00-3.960.000.000.00
Stock Option Compensation Expense0.831.020.710.530.150.150.130.12
Price To Sales Ratio7.175.2113.6313.9713.682.661.162.00
Gross Margin63.2689.4093.2793.8493.8182.9183.5784.07
Operating Margin-2,203.65-692.51-420.04-320.83-110.65-333.90-276.20-260.92
Net Margin-2,191.24-675.68-417.92-316.6185.68-1,643.15-276.42-197.39
Shares Outstanding7.315.565.555.263.690.680.240.24
Market Capitalization5.8522.5971.0489.9832.0616.156.788.61

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments13.113.618.5518.1218.408.3517.595.3010.22
Short Term Receivables0.320.570.000.000.000.001.310.230.26
Inventories0.000.000.000.000.000.000.110.113.18
Other Current Assets1.340.651.283.701.320.830.814.011.20
Total Current Assets14.784.829.8321.8219.729.1819.829.6514.86
Net Property, Plant & Equipment0.330.521.111.571.822.462.962.303.05
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.700.840.410.470.420.460.370.3711.13
Other Assets0.520.450.030.010.020.020.0711.672.57
Total Assets16.326.6311.3923.8721.9812.1123.2323.9931.61
Short Term Debt Incl. Current Port. of LT Debt0.813.344.101.721.726.4711.3314.2013.62
Accounts Payable3.289.474.768.362.610.790.330.721.30
Other Current Liabilities8.232.741.871.771.541.282.832.643.49
Total Current Liabilities12.3115.5510.7311.855.878.5414.4917.5618.41
Long Term Debt0.010.030.093.935.270.530.650.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.001.921.640.000.016.941.210.20
Total Liabilities12.3315.5812.7417.4211.149.0722.0718.7718.61
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity4.00-8.95-1.356.4510.843.031.165.2213.00
Total Shareholders Equity4.00-8.95-1.356.4510.843.031.165.2213.00
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity4.00-8.95-1.356.4510.843.031.165.2213.00
Total Liabilities & Stockholders Equity16.326.6311.3923.8721.9812.1123.2323.9931.61
Book Value Per Share0.72-37.94-7.4571.93261.99168.41112.106,605.92421,525.14
Tangible Book Value Per Share0.59-41.51-9.7466.73251.76142.9776.156,135.6060,667.20
Full-Time Employees282120171412123737
Price to Book Ratio1.03-0.763.020.911.504.508.030.821.34
Return on Assets-195.02-144.03-75.54-88.44-78.62-46.65-13.91-31.93-80.52
Return on Equity---522.50-234.65-193.25-393.27-102.83-97.43-222.32
Return on Invested Capital-558.12---195.48-83.17-231.55-242.47-241.80-205.10
Quick Ratio1.200.310.921.843.361.071.360.540.63
Current Ratio1.200.310.921.843.361.071.370.550.81

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-26.09-22.39-12.98-13.32-20.27-13.40-8.24-10.89-12.63
Depreciation0.440.450.850.740.710.420.370.912.00
Other Funds (Non Cash)3.117.21-1.650.840.991.46-0.685.01-0.31
Funds from Operations-22.54-14.73-13.78-11.73-18.57-11.52-8.55-4.97-10.94
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.36-6.043.22-1.125.601.240.12-0.94-1.03
Cash from Operating Activities-22.18-20.77-10.55-12.85-12.97-10.28-8.43-5.91-11.97
Capital Expenditures-1.37-0.07-0.69-0.16-0.51-0.14-0.09-0.07-0.13
Net Assets From Acquisitions0.000.000.000.00-0.250.00-0.400.000.00
Sale of Fixed Assets and Businesses0.000.030.000.000.000.060.005.640.00
Purchase or Sale of Investments-5.34-4.58-3.420.000.000.000.000.000.00
Purchase of Investments-15.65-9.35-15.590.000.000.000.000.000.00
Sale Or Maturity of Investments10.304.7712.170.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources3.773.770.000.000.000.000.000.000.00
Cash from Investing Activities-2.95-0.85-4.11-0.16-0.76-0.08-0.495.57-0.13
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock11.7115.706.895.0515.0620.695.1116.457.23
Repurchase of Common Pref Stock0.220.00-0.37-0.470.000.000.000.000.00
Sale of Common Pref Stock11.4915.707.265.5315.0620.695.1116.457.23
Proceedsfrom Stock Options-3.55-0.230.005.5315.0618.684.0115.967.23
Issuance or Reduction of Debt, Net1.47-4.76-0.70-1.61-1.61-0.28-5.42-3.820.00
Change in Long Term Debt1.49-2.21-4.00-1.61-1.61-0.28-5.42-3.820.00
Issuance of Long Term Debt1.491.490.000.000.000.000.000.000.00
Reduction of Long Term Debt0.00-3.70-4.00-1.61-1.61-0.28-5.42-3.820.00
Net Financing Active Other Cash Flow12.0819.370.000.000.000.000.000.00-0.07
Other Financing Activities Uses-7.74-3.240.000.000.000.000.000.00-0.07
Cash from Financing Activities25.2530.316.193.4413.4520.42-0.3212.637.17
Exchange Rate Effect------0.00-0.000.02
Net Change in Cash0.138.68-8.48-9.57-0.2810.05-9.2512.29-4.92
Free Cash Flow-23.55-20.84-10.70-13.01-13.48-10.42-8.53-5.97-12.11
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments8.5915.1113.1116.606.889.87
Short Term Receivables1.971.350.320.001.020.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.971.151.340.690.870.56
Total Current Assets11.5317.6114.7817.298.7710.42
Net Property, Plant & Equipment1.451.070.330.290.320.36
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.640.670.700.750.770.81
Other Assets0.410.560.520.340.490.46
Total Assets14.0319.9216.3218.6710.3512.06
Short Term Debt Incl. Current Port. of LT Debt0.040.720.810.020.030.04
Accounts Payable7.556.165.9211.626.369.22
Other Current Liabilities0.971.075.591.970.931.30
Total Current Liabilities8.577.9612.3113.627.3210.56
Long Term Debt0.000.000.010.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.0025.14
Total Liabilities8.577.9612.3313.627.3235.70
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.4611.964.005.053.03-23.64
Total Shareholders Equity5.4611.964.005.053.03-23.64
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.4611.964.005.053.03-23.64
Total Liabilities & Stockholders Equity14.0319.9216.3218.6710.3512.06
Book Value Per Share0.752.150.720.960.82-34.77
Tangible Book Value Per Share0.662.030.590.820.61-35.95
Full-Time Employees--28---
Price to Book Ratio1.031.8917.7817.8010.57-0.68
Return on Assets-214.01-99.41-229.51-191.33-213.22-306.82
Return on Equity-614.05-----
Return on Invested Capital-164.85-58.07-142.43-87.5139.26-
Quick Ratio1.352.211.201.271.200.99
Current Ratio1.352.211.201.271.200.99

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.01-6.95-5.71-4.425.15-17.40
Depreciation0.150.110.090.090.090.18
Other Funds (Non Cash)0.841.020.720.53-6.5312.49
Funds from Operations-8.01-5.82-4.90-3.81-1.29-4.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.88-0.42-1.361.26-4.50-1.44
Cash from Operating Activities-7.13-6.24-6.26-2.55-5.80-6.17
Capital Expenditures-0.50-0.82-0.02-0.03-0.01-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.03
Purchase or Sale of Investments5.87-7.71-4.821.33-4.623.53
Purchase of Investments-4.35-9.701.72-3.31-7.760.00
Sale Or Maturity of Investments10.211.99-6.544.643.133.53
Other Uses0.000.000.000.000.000.00
Other Sources0.000.003.770.000.000.00
Cash from Investing Activities5.37-8.53-1.081.30-4.633.56
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.7813.64-0.00-3.710.0019.40
Repurchase of Common Pref Stock0.000.000.000.22-0.220.00
Sale of Common Pref Stock1.7813.64-0.00-3.920.2219.40
Proceedsfrom Stock Options1.7813.640.00-18.970.2218.52
Issuance or Reduction of Debt, Net-0.67-0.100.751.490.00-7.00
Change in Long Term Debt0.000.000.001.490.00-3.70
Issuance of Long Term Debt0.000.00-2.253.740.000.00
Reduction of Long Term Debt0.000.002.25-2.250.00-3.70
Net Financing Active Other Cash Flow0.00-4.502.0514.522.790.00
Other Financing Activities Uses0.00-4.50-0.95-2.290.000.00
Cash from Financing Activities1.119.042.8012.312.8012.40
Net Change in Cash-0.66-5.74-4.5311.06-7.639.79
Free Cash Flow-7.63-7.06-6.29-2.58-5.80-6.17

Revenue breakdown

Consolidation, Policy2024: 24.00K 2025: 13.00K
Grant2024: 5.80M 2025: 5.20M
United States2024: 5.82M 2025: 5.21M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.27%0.8M7.5M108.75K
2026-10-1510.44%0.8M7.5M112.66K
2026-09-3010.00%0.7M7.5M103.01K
2026-09-158.67%0.7M7.5M129.37K
2026-08-318.64%0.6M7.5M137.45K
2026-08-148.32%0.6M7.5M153.85K
2026-07-1510.42%0.7M6.8M197.19K
2026-06-3014.84%1.0M6.8M332.72K
2026-06-1516.31%1.1M6.8M303.42K
2026-05-2916.73%1.1M6.8M312.04K
2026-05-1516.99%1.2M6.8M317.54K
2026-04-3018.08%1.2M6.8M348.38K
2026-04-1519.77%1.3M6.8M443.87K
2026-03-31-1.0M-393.41K
2026-03-1311.77%0.8M6.8M382.23K
2026-02-2711.34%0.8M7.1M387.35K
2026-02-1313.73%1.0M7.1M398.08K
2026-01-3013.55%1.0M7.1M377.97K
2026-01-156.40%0.5M7.1M301.67K
2025-12-315.36%0.3M5.5M340.50K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-124Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-10-028-KCurrent report2026-10-02SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-18DNotice of sales of securities on Form D (Regulation D)SEC
2026-09-108-KCurrent report2026-09-04SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-048-KCurrent report2026-08-03SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-18S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-05EFFECTEffectiveness filing by commission orderSEC
2026-06-058-KCurrent report2026-06-01SEC
2026-06-05CORRESPSEC
2026-06-05S-3/ASEC
2026-06-04UPLOADUpload SubmissionSEC
2026-06-02S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC
2026-05-184Statement of changes in beneficial ownership of securities2026-05-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-1110.20K100

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.43%
BlackRock, Inc.1.39%
GEODE CAPITAL MANAGEMENT, LLC1.08%
VANGUARD FIDUCIARY TRUST CO0.54%
Ashton Thomas Private Wealth, LLC0.45%
STATE STREET CORP0.41%
CITADEL ADVISORS LLC0.37%
NORTHERN TRUST CORP0.23%
Virtu Financial LLC0.22%
HRT FINANCIAL LP0.17%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.54%
Fidelity Series Total Market Index Fund0.17%
Fidelity Total Market Index Fund0.13%
Fidelity Nasdaq Composite Index Fund0.04%

OakChart. CNSY. Cached 15 minutes. Terms